Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
11.19
+1.66 (17.42%)
At close: Feb 26, 2026, 4:00 PM EST
11.09
-0.10 (-0.89%)
After-hours: Feb 26, 2026, 6:51 PM EST

Novavax Revenue

In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. Novavax had revenue of $147.14M in the quarter ending December 31, 2025, with 66.61% growth.

Revenue (ttm)
$1.12B
Revenue Growth
+64.69%
P/S Ratio
1.62
Revenue / Employee
$1,180,125
Employees
952
Market Cap
1.82B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020475.60M456.94M2,448.48%
Dec 31, 201918.66M-15.63M-45.57%
Dec 31, 201834.29M3.11M9.98%
Dec 31, 201731.18M15.82M103.06%
Dec 31, 201615.35M-20.90M-57.65%
Dec 31, 201536.25M5.59M18.24%
Dec 31, 201430.66M9.74M46.59%
Dec 31, 201320.92M-1.16M-5.26%
Dec 31, 201222.08M7.39M50.30%
Dec 31, 201114.69M14.35M4,182.22%
Dec 31, 2010343.00K18.00K5.54%
Dec 31, 2009325.00K-739.00K-69.45%
Dec 31, 20081.06M-449.00K-29.68%
Dec 31, 20071.51M-225.00K-12.95%
Dec 31, 20061.74M-3.61M-67.47%
Dec 31, 20055.34M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Iovance Biotherapeutics263.50M
AnaptysBio169.47M
Intellia Therapeutics57.53M
uniQure15.75M
Relay Therapeutics8.36M
AtaiBeckley3.02M
Revenue Rankings